Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10347678 | 0.83 | — | — | |
| SCHEMBL9016828 | 0.82 | SLC6A3 (0.51) | SLC6A3 | |
| SCHEMBL2577670 | 0.82 | SLC6A3 (0.65) | SLC6A3 | |
| SCHEMBL6074896 | 0.81 | SLC6A3 (0.65) | SLC6A3 | |
| SCHEMBL16011837 | 0.81 | ALDH1A1 (0.51) | SLC6A3 | |
| Hydrochloric Acid SCHEMBL2577794 | 0.80 | SLC6A3 (0.62) | SLC6A3 | |
| SCHEMBL10334603 | 0.77 | PDPK1 (0.60) | SLC6A3 | |
| SCHEMBL9016825 | 0.77 | ALDH1A1 (0.54) | SLC6A3 | |
| SCHEMBL9016821 | 0.77 | FFAR1 (0.47) | SLC6A3 | |
| SCHEMBL24871095 | 0.76 | MAPT (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555013-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2023281095-A1 | LAUFLUMIDE AND DERIVATIVES THEREOF FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) | NLS PHARMACEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| EP-2964611-B1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20210130288-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-05-06 | — | — | US | disclosed |
| US-10913711-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-09 | — | — | US | disclosed |
| US-10590074-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190185424-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2019-06-20 | — | — | US | disclosed |
| US-20180093947-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2018-04-05 | — | — | US | disclosed |
| US-9862679-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160009644-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | The United States of America, as represented by th Secretary, Department of Health and Human Service (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2964611-A2 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138518-A2 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-12 | — | — | WO | disclosed |
| US-5571825-A | Method of selectively inhibiting prostaglandin G/H synthase-2 | WARNER-LAMBERT COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185424-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885 |
| US-10590074-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885 |
| US-20210130288-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885 |
| US-20160009644-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885 |
| US-11555013-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885 |
| US-20180093947-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885 |
| US-10913711-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.